Amycretin

Synonyms: LY3305677, OXM-3 analog, GLP-1/glucagon receptor dual agonist

Amycretin is a synthetic peptide engineered as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors, developed for the treatment of obesity and metabolic disorders. It is produced via solid-phase peptide synthesis and supplied as a high-purity lyophilized powder, suitable for research and pharmaceutical development.

As a next-generation incretin-based therapy, Amycretin aims to harness the complementary effects of GLP-1 and glucagon receptor activation to achieve superior weight loss and glycemic control. Its unique mechanism positions it as a promising candidate in the competitive landscape of anti-obesity medications.

Product Highlights

• High Purity: ≥98% purity confirmed by HPLC, ensuring reliable experimental results.
• Dual Receptor Agonism: Simultaneously targets GLP-1 and glucagon receptors for enhanced metabolic benefits.
• Scalable Production: Manufactured under cGMP conditions with robust supply chain for large-scale needs.
• Comprehensive Documentation: Each batch includes a detailed COA, MSDS, and TDS for regulatory compliance.
• Custom Packaging: Available in various sizes to accommodate different research and production scales.

Applications

• Preclinical and clinical research on obesity and type 2 diabetes.
• Studies investigating dual receptor agonism mechanisms.
• Development of novel peptide-based therapeutics.
• Metabolic disease model testing.

Specifications

Ordering & Supply

• Packaging: Supplied in lyophilized powder form in sealed vials.
• MOQ: 1 mg.
• Lead time: 3-5 business days (stock items)
• Documentation: COA, MSDS, TDS provided with each shipment.

Request For Quote

• LyvBio Co., Ltd. — Email: info@lyvbio.com